GENE DELIVERY TECHNOLOGIES MARKET GLOBAL ANALYSIS REPORT 2025-230 Published by: Priti, Healthcare
Market Size & Overview: As of 2023, the Gene Delivery Technologies Market was valued at approximately USD 4.51 billion. It is projected to grow at a compound annual growth rate (CAGR) of 12.2% from 2024 to 2030, potentially reaching around USD 10.10 billion by the end of the forecast period. Gene delivery technology encompasses three primary components: a gene encoding a specific therapeutic protein, a plasmid-based gene expression system to regulate gene function within the target cell, and a delivery mechanism to transport the gene expression plasmid to the desired location in the body. A successful gene delivery system ensures that the introduced genetic material remains stable within the host cell.
Market Growth & Opportunities Advancements in nanotechnology and physical methods have led to the development of innovative gene delivery techniques such as magnetoporation,optoporation, sonoporation, and electroporation. These methods are gaining traction due to their enhanced functionality and nontoxic nature. For instance, in 2021, Thermo Fisher Scientific invested USD 180 million to construct a new 290,000-square-foot facility in Plainville, MA, aiming to expand capacity for viral vector development and manufacturing services. Sample Request
Market Segmentation by Mode • Biological • Chemical • Physical by Method • Ex vivo • In Vivo • In Vitro by End User • Gene Therapy • Cell Therapy • Vaccines • Research
Regional Analysis: North America: This region leads the gene delivery technologies market, driven by substantial investments in research and development, a robust biotechnology sector, and supportive regulatory frameworks. Europe: Europe holds a significant market share, attributed to collaborative research initiatives, well-established healthcare infrastructure, and increasing adoption of advanced gene therapies. Asia-Pacific (APAC): APAC is experiencing rapid growth in the gene delivery technologies market, propelled by rising healthcare expenditures, expanding biotechnology industries, and growing awareness of gene therapies in countries like China and India.
Regional Analysis North America Europe Asia Pacific Middle East and Africa South America Regional Analysis 2025-2030 Customized Report Request
Merges and Acquisition Thermo Fisher Scientific's Acquisition of Brammer Bio: In 2019, Thermo Fisher Scientific acquired Brammer Bio for USD 1.7 billion, enhancing its capabilities in viral vector manufacturing for gene therapies. Catalent's Acquisition of Paragon Bioservices: Also in 2019, Catalent acquired Paragon Bioservices for USD 1.2 billion, strengthening its position in the gene therapy market by expanding its viral vector development and manufacturing services. Thermo Fisher Scientific's Investment in Plainville Facility: In 2021, Thermo Fisher Scientific invested USD 180 million to construct a new facility in Plainville, MA, doubling its capacity for viral vector development and manufacturing services. Buy This Report
Thank You Get In Touch with US: MAXIMIZE MARKET RESEARCH PVT. LTD. 3rd Floor, Navale IT park Phase 2, Pune Banglore Highway, Narhe Pune, Maharashtra 411041, India. +91 9607365656 [email protected]